뉴로펩타이드 S

Neuropeptide S
NPS
식별자
에일리어스NPS, 신경펩타이드S
외부 IDOMIM: 609513 MGI: 3642232 HomoloGene: 106066 GeneCard: NPS
맞춤법
종.인간마우스
엔트레즈

594857

100043254

앙상블

ENSG00000214285

ENSMUSG000073804

유니프로트

P0C0P6

P0C0P8

RefSeq(mRNA)

NM_001030013

NM_001163611

RefSeq(단백질)

NP_001025184

NP_001157083

장소(UCSC)Chr 10: 127.55 ~127.55 MbChr 7: 134.86 ~134.87 Mb
PubMed 검색[3][4]
위키데이터
인간 보기/편집마우스 표시/편집

NPS(Neuro 펩타이드 S)는 인간과 포유류의 뇌에서 발견되는 신경펩타이드로, 주로 편도체의 뉴런과 배링턴의 핵과 궤적 강압 사이에 생성되지만, NPS 반응 뉴런은 다른 많은 뇌 [5][6][7]영역으로 돌출되어 있다.NPS는 G단백질결합수용체 NPSR에 [8][9]특이적으로 결합한다.동물 연구는 NPS가 불안과 식욕을 억제하고, 과도한 성욕을 포함한 각성과 과잉행동을 유발하며, 조건부 [10][11][12][13][14][15][16]공포의 소멸에 중요한 역할을 한다는 것을 보여준다.또한 랫드 및 [17]인간에서 중림부 [16]경로의 도파민 활성을 유의하게 증강하고 운동성을 억제하고 장내 신경총의 NO를 통해 작용하는 신경크린 방식의 투과성을 증가시키는 것으로 나타났다.

합성 배위자

비펩타이드 NPS 수용체 길항제 SHA-68은 동물에서 NPS의 영향을 차단하고 강산성을 [18]일으킨다.또한 몇몇 펩타이드 유도 NPS 작용제 및 길항제도 [19][20][21][22][23]개발되었습니다.

펩타이드 배열

다음은 발현되는 여러 대표적인 종에서 성숙한 신경펩타이드 S의 염기서열이다.

뉴로펩타이드 S
식별자
기호.신경펩타이드_s
팜PF14993
인터프로IPR028138
종. 순서 MW
인간적인 SFRNGVGTGMKKTSFQRAKS 2187.5
쥐. SFRNGVGSGVKKTSFRRAKQ 2210.5
마우스 SFRNGVGSGAKKTSFRRAKQ 2182.5
개, 침팬지 SFRNGVGTGMKKTSFRRAKS 2215.6
치킨. SFRNGVGSGIKKTSFRRAKS 2183.5
컨센서스 SFRNGVGxGXKKTSFxRAKx 없음

Pfam의 HMM 로고에 따르면, C 말단 성숙한 펩타이드 바로 N 말단으로 보존된 "KR" 절단 부위가 있다.

레퍼런스

  1. ^ a b c GRCh38: 앙상블 릴리즈 89: ENSG00000214285 - 앙상블, 2017년 5월
  2. ^ a b c GRCm38: 앙상블 릴리즈 89: ENSMUSG000073804 - 앙상블, 2017년 5월
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Xu YL, Gall CM, Jackson VR, Civelli O, Reinscheid RK (Jan 2007). "Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain". The Journal of Comparative Neurology. 500 (1): 84–102. doi:10.1002/cne.21159. PMID 17099900. S2CID 23864785.
  6. ^ Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, Okamura N, Duangdao DM, Xu YL, Reinscheid RK, Pape HC (Jul 2008). "Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala". Neuron. 59 (2): 298–310. doi:10.1016/j.neuron.2008.07.002. PMC 2610688. PMID 18667157.
  7. ^ Meis S, Bergado-Acosta JR, Yanagawa Y, Obata K, Stork O, Munsch T (2008). Grothe B (ed.). "Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus". PLOS ONE. 3 (7): e2695. doi:10.1371/journal.pone.0002695. PMC 2442874. PMID 18628994. open access
  8. ^ Reinscheid RK, Xu YL (Dec 2005). "Neuropeptide S and its receptor: a newly deorphanized G protein-coupled receptor system". The Neuroscientist. 11 (6): 532–8. doi:10.1177/1073858405276405. PMID 16282594. S2CID 30579961.
  9. ^ Reinscheid RK (2008). "Neuropeptide S: anatomy, pharmacology, genetics and physiological functions". Results and Problems in Cell Differentiation. 46: 145–58. doi:10.1007/400_2007_051. ISBN 978-3-540-78350-3. PMID 18204825.
  10. ^ Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O (Aug 2004). "Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects". Neuron. 43 (4): 487–97. doi:10.1016/j.neuron.2004.08.005. PMID 15312648. S2CID 15601843.
  11. ^ Reinscheid RK, Xu YL (Nov 2005). "Neuropeptide S as a novel arousal promoting peptide transmitter". The FEBS Journal. 272 (22): 5689–93. doi:10.1111/j.1742-4658.2005.04982.x. PMID 16279934. S2CID 42586325.
  12. ^ Okamura N, Reinscheid RK (Aug 2007). "Neuropeptide S: a novel modulator of stress and arousal". Stress. 10 (3): 221–6. doi:10.1080/10253890701248673. PMID 17613937. S2CID 39068808.
  13. ^ Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, Malberg JE, Beyer CE, Schechter LE, Rosenzweig-Lipson S, Ring RH (May 2008). "Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders". Psychopharmacology. 197 (4): 601–11. doi:10.1007/s00213-008-1080-4. PMID 18311561. S2CID 21120092.
  14. ^ Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, Regoli D, Calo G (May 2008). "Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice". British Journal of Pharmacology. 154 (2): 471–9. doi:10.1038/bjp.2008.96. PMC 2442439. PMID 18376418.
  15. ^ Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A, Guerrini R, Calò G (Dec 2008). "Anxiolytic-like effect of neuropeptide S in the rat defensive burying". Peptides. 29 (12): 2286–91. doi:10.1016/j.peptides.2008.08.014. hdl:11380/610466. PMID 18793688. S2CID 207356961.
  16. ^ a b Mochizuki T, Kim J, Sasaki K (May 2010). "Microinjection of neuropeptide S into the rat ventral tegmental area induces hyperactivity and increases extracellular levels of dopamine metabolites in the nucleus accumbens shell". Peptides. 31 (5): 926–31. doi:10.1016/j.peptides.2010.02.006. PMID 20156501. S2CID 19981059.
  17. ^ Wan Saudi WS, Halim MA, Rudholm-Feldreich T, Gillberg L, Rosenqvist E, Tengholm A, Sundbom M, Karlbom U, Näslund E, Webb DL, Sjöblom M, Hellström PM (Oct 2015). "Neuropeptide S inhibits gastrointestinal motility and increases mucosal permeability through nitric oxide". Am J Physiol Gastrointest Liver Physiol. 309 (9): G625-34. doi:10.1152/ajpgi.00104.2015. PMID 26206857. S2CID 5560949.
  18. ^ Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (Jun 2008). "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 893–901. doi:10.1124/jpet.107.135103. PMC 2583099. PMID 18337476.
  19. ^ Roth AL, Marzola E, Rizzi A, Arduin M, Trapella C, Corti C, Vergura R, Martinelli P, Salvadori S, Regoli D, Corsi M, Cavanni P, Caló G, Guerrini R (Jul 2006). "Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation". The Journal of Biological Chemistry. 281 (30): 20809–16. doi:10.1074/jbc.M601846200. PMID 16720571.
  20. ^ Camarda V, Trapella C, Calo G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (Feb 2008). "Synthesis and biological activity of human neuropeptide S analogues modified in position 2". Journal of Medicinal Chemistry. 51 (3): 655–8. doi:10.1021/jm701204n. PMID 18181564.
  21. ^ Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (Oct 2008). "Structure-activity study at positions 3 and 4 of human neuropeptide S". Bioorganic & Medicinal Chemistry. 16 (19): 8841–5. doi:10.1016/j.bmc.2008.08.073. PMID 18793857.
  22. ^ Guerrini R, Camarda V, Trapella C, Calò G, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (Jan 2009). "Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists". Journal of Medicinal Chemistry. 52 (2): 524–9. doi:10.1021/jm8012294. PMC 2653091. PMID 19113861.
  23. ^ Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK, Regoli D, Calò G (Feb 2009). "In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S". The Journal of Pharmacology and Experimental Therapeutics. 328 (2): 549–55. doi:10.1124/jpet.108.143867. PMC 2630366. PMID 18971372.